Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             289 results found
no title author magazine year volume issue page(s) type
1 A candidate dual vaccine against influenza and noroviruses Xia, Ming
 2011
 29 Supplement 2 p. 7670-7677
8 p.
 article
2 A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus–poxvirus prime boost immunisations Ranasinghe, Charani
 2011
 29 Supplement 2 p. 3008-3020
13 p.
 article
3 A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets Giles, Brendan M.
 2011
 29 Supplement 2 p. 3043-3054
12 p.
 article
4 Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces—2009–2010 Mayet, Aurélie
 2011
 29 Supplement 2 p. 2576-2581
6 p.
 article
5 Afriflu—International conference on influenza disease burden in Africa, 1–2 June 2010, Marrakech, Morocco Steffen, C.
 2011
 29 Supplement 2 p. 363-369
7 p.
 article
6 Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection van Dissel, Jaap T.
 2011
 29 Supplement 2 p. 2100-2109
10 p.
 article
7 A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy Mo, Annie
 2011
 29 Supplement 2 p. 8530-8541
12 p.
 article
8 A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness Gunther, V.J.
 2011
 29 Supplement 2 p. 3895-3904
10 p.
 article
9 A live attenuated strain of Yersinia pestis KIM as a vaccine against plague Sun, Wei
 2011
 29 Supplement 2 p. 2986-2998
13 p.
 article
10 Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques Carroll, Timothy D.
 2011
 29 Supplement 2 p. 931-940
10 p.
 article
11 A mucosal vaccination approach for herpes simplex virus type 2 Tirabassi, Rebecca S.
 2011
 29 Supplement 2 p. 1090-1098
9 p.
 article
12 A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity Even-Or, Orli
 2011
 29 Supplement 2 p. 2474-2486
13 p.
 article
13 A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV) Rohde, Joerg
 2011
 29 Supplement 2 p. 9256-9264
9 p.
 article
14 An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults Talaat, Kawsar R.
 2011
 29 Supplement 2 p. 3144-3148
5 p.
 article
15 Antibody persistence at 18–20months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China Li, Rong Cheng
 2011
 29 Supplement 2 p. 9337-9344
8 p.
 article
16 Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children Meier, Sara
 2011
 29 Supplement 2 p. 3548-3557
10 p.
 article
17 A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients Staff, Caroline
 2011
 29 Supplement 2 p. 6817-6822
6 p.
 article
18 A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression Keiser, P.B.
 2011
 29 Supplement 2 p. 1413-1420
8 p.
 article
19 A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1 Tetteh, Kevin K.A.
 2011
 29 Supplement 2 p. 7811-7817
7 p.
 article
20 A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years Tennis, Patricia
 2011
 29 Supplement 2 p. 4947-4952
6 p.
 article
21 A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older Forrest, Bruce D.
 2011
 29 Supplement 2 p. 3633-3639
7 p.
 article
22 A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults Block, Stan L.
 2011
 29 Supplement 2 p. 9391-9397
7 p.
 article
23 A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants Bernstein, David I.
 2011
 29 Supplement 2 p. 7042-7048
7 p.
 article
24 A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years Schwarz, T.F.
 2011
 29 Supplement 2 p. 5195-5202
8 p.
 article
25 ArtinM, a d-mannose-binding lectin from Artocarpus integrifolia, plays a potent adjuvant and immunostimulatory role in immunization against Neospora caninum Cardoso, Mariana R.D.
 2011
 29 Supplement 2 p. 9183-9193
11 p.
 article
26 A single immunization near birth elicits immediate and lifelong protective immunity Reikie, Brian A.
 2010
 29 Supplement 2 p. 83-90
8 p.
 article
27 Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad Zipursky, Simona
 2011
 29 Supplement 2 p. 5652-5656
5 p.
 article
28 A survey of children's preferences for influenza vaccine attributes Flood, Emuella M.
 2011
 29 Supplement 2 p. 4334-4340
7 p.
 article
29 A systematic review of intradermal influenza vaccines Young, Flora
 2011
 29 Supplement 2 p. 8788-8801
14 p.
 article
30 Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: Development and validation of an evidence-based measurement instrument Brown, Katrina F.
 2011
 29 Supplement 2 p. 1700-1709
10 p.
 article
31 Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl Corte, Claudia Della
 2011
 29 Supplement 2 p. 4654-4656
3 p.
 article
32 Bioprocess optimization for cell culture based influenza vaccine production Aggarwal, Kunal
 2011
 29 Supplement 2 p. 3320-3328
9 p.
 article
33 Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies Pusic, Kae
 2011
 29 Supplement 2 p. 8898-8908
11 p.
 article
34 Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves Hägglund, Sara
 2011
 29 Supplement 2 p. 8719-8730
12 p.
 article
35 Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania Bakari, Muhammad
 2011
 29 Supplement 2 p. 8417-8428
12 p.
 article
36 Canadian paediatricians’ opinions on rotavirus vaccination Dubé, E.
 2011
 29 Supplement 2 p. 3177-3182
6 p.
 article
37 Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunisation of sheep Bouet-Cararo, Coraline
 2011
 29 Supplement 2 p. 1304-1310
7 p.
 article
38 Change in hepatitis A epidemiology after vaccinating high risk children in Taiwan, 1995–2008 Tsou, Tsung-Pei
 2011
 29 Supplement 2 p. 2956-2961
6 p.
 article
39 Changes in serotype distribution of Haemophilus influenzae meningitis isolates identified through laboratory-based surveillance following routine childhood vaccination against H. influenzae type b in Brazil Zanella, Rosemeire C.
 2011
 29 Supplement 2 p. 8937-8942
6 p.
 article
40 Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines Westdijk, Janny
 2011
 29 Supplement 2 p. 3390-3397
8 p.
 article
41 Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine Adler-Moore, Jill
 2011
 29 Supplement 2 p. 4460-4468
9 p.
 article
42 Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007–2009) laboratory-based surveillance in Madrid Picazo, J.
 2011
 29 Supplement 2 p. 1770-1776
7 p.
 article
43 Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2 Kim, D.
 2011
 29 Supplement 2 p. 3206-3212
7 p.
 article
44 Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose Zheng, Hui
 2011
 29 Supplement 2 p. 9098-9103
6 p.
 article
45 Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis Scott, Pippa
 2011
 29 Supplement 2 p. 9711-9721
11 p.
 article
46 Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e Park, Ki Seok
 2011
 29 Supplement 2 p. 5481-5487
7 p.
 article
47 Construction and immunogenicity of recombinant adenovirus expressing ORF2 of PCV2 and porcine IFN gamma Genmei, Liu
 2011
 29 Supplement 2 p. 8677-8682
6 p.
 article
48 Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen Vu, David M.
 2011
 29 Supplement 2 p. 1968-1973
6 p.
 article
49 Coverage and side effects of influenza A(H1N1) 2009 monovalent vaccine among primary health care workers Arjona, Miguel Angel Ortiz
 2011
 29 Supplement 2 p. 6366-6368
3 p.
 article
50 Coxiella burnetii DNA in goat milk after vaccination with Coxevac® Hermans, Mirjam H.A.
 2011
 29 Supplement 2 p. 2653-2656
4 p.
 article
51 Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals Rohani, Md Yasin
 2011
 29 Supplement 2 p. 5688-5693
6 p.
 article
52 Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice Farag, Mohamed M.S.
 2010
 29 Supplement 2 p. 200-206
7 p.
 article
53 Determinants of A (H1N1) vaccination: Cross-sectional study in a population of pregnant women in Quebec Fabry, Paul
 2011
 29 Supplement 2 p. 1824-1829
6 p.
 article
54 Determination of antigenic properties of vaccine derived poliovirus strains Pliaka, Vaia
 2010
 29 Supplement 2 p. 26-33
8 p.
 article
55 Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 Fomsgaard, Anders
 2011
 29 Supplement 2 p. 7067-7074
8 p.
 article
56 Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2 Posavad, Christine M.
 2011
 29 Supplement 2 p. 7058-7066
9 p.
 article
57 Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever Osorio, Jorge E.
 2011
 29 Supplement 2 p. 7251-7260
10 p.
 article
58 Development of DIVA (differentiation of infected from vaccinated animals) vaccines utilizing heterologous NA and NS1 protein strategies for the control of triple reassortant H3N2 influenza in turkeys Wang, Leyi
 2011
 29 Supplement 2 p. 7966-7974
9 p.
 article
59 Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: Addressing the threat of an influenza pandemic Surichan, Somchaiya
 2011
 29 Supplement 2 p. A29-A33
nvt p.
 article
60 Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e Li, Rui
 2011
 29 Supplement 2 p. 5502-5511
10 p.
 article
61 Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine Somech, Ido
 2011
 29 Supplement 2 p. 4202-4209
8 p.
 article
62 Divergence of immunologic and protective responses of different BCG strains in a murine model Kozak, R.
 2011
 29 Supplement 2 p. 1519-1526
8 p.
 article
63 Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates Marsh, Jane W.
 2011
 29 Supplement 2 p. 6049-6058
10 p.
 article
64 DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge Lu, Yu-Chun
 2011
 29 Supplement 2 p. 7740-7746
7 p.
 article
65 Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older Lode, H.
 2011
 29 Supplement 2 p. 4940-4946
7 p.
 article
66 Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece Grivea, Ioanna N.
 2011
 29 Supplement 2 p. 8882-8887
6 p.
 article
67 Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan Fredriksen, B.N.
 2011
 29 Supplement 2 p. 8338-8349
12 p.
 article
68 Economic analysis of the global polio eradication initiative Duintjer Tebbens, Radboud J.
 2010
 29 Supplement 2 p. 334-343
10 p.
 article
69 Editorial Board 2011
 29 Supplement 2 p. CO2-
1 p.
 article
70 Editorial Board 2011
 29 Supplement 2 p. CO2-
1 p.
 article
71 Editorial Board 2011
 29 Supplement 2 p. CO2-
1 p.
 article
72 Editorial Board 2011
 29 Supplement 2 p. CO2-
1 p.
 article
73 Effectiveness and safety of influenza vaccination in children: European perspective Heikkinen, Terho
 2011
 29 Supplement 2 p. 7529-7534
6 p.
 article
74 Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand Arnold, Richard
 2011
 29 Supplement 2 p. 7100-7106
7 p.
 article
75 Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine Miller, Elizabeth
 2011
 29 Supplement 2 p. 9127-9131
5 p.
 article
76 Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case–control study Mahmud, Salaheddin
 2011
 29 Supplement 2 p. 7975-7981
7 p.
 article
77 Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study Domínguez, Angela
 2011
 29 Supplement 2 p. 9020-9025
6 p.
 article
78 Effect of GonaCon™ vaccine on black-tailed prairie dogs: Immune response and health effects Yoder, Christi A.
 2010
 29 Supplement 2 p. 233-239
7 p.
 article
79 Effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the immune responses to Newcastle disease vaccine in chickens Zhai, Lijuan
 2011
 29 Supplement 2 p. 5007-5014
8 p.
 article
80 Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial van Gils, Elske J.M.
 2011
 29 Supplement 2 p. 7595-7598
4 p.
 article
81 Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig Bernstein, David I.
 2011
 29 Supplement 2 p. 2071-2078
8 p.
 article
82 Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection Leng, Jin
 2011
 29 Supplement 2 p. 8147-8155
9 p.
 article
83 Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers Chakvetadze, Catherine
 2011
 29 Supplement 2 p. 2846-2849
4 p.
 article
84 Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life Kawamura, Naohisa
 2011
 29 Supplement 2 p. 6335-6341
7 p.
 article
85 Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model Park, Jung-Sun
 2011
 29 Supplement 2 p. 8642-8648
7 p.
 article
86 Emerging and continuing trends in vaccine opposition website content Bean, Sandra J.
 2011
 29 Supplement 2 p. 1874-1880
7 p.
 article
87 Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes Rosenkrands, Ida
 2011
 29 Supplement 2 p. 6283-6291
9 p.
 article
88 Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine Huang, Xianming
 2011
 29 Supplement 2 p. 4785-4793
9 p.
 article
89 Epidemiology and transmission dynamics of the 1918–19 pandemic influenza in Florence, Italy Rizzo, Caterina
 2011
 29 Supplement 2 p. B27-B32
nvt p.
 article
90 Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection Zheng, Qun
 2011
 29 Supplement 2 p. 763-771
9 p.
 article
91 Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen Nagendrakumar, Singanallur Balasubramanian
 2011
 29 Supplement 2 p. 1906-1912
7 p.
 article
92 Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products Parveen, Seema
 2011
 29 Supplement 2 p. 8012-8023
12 p.
 article
93 Evaluation of hha and hha sepB mutant strains of Escherichia coli O157:H7 as bacterins for reducing E. coli O157:H7 shedding in cattle Sharma, Vijay K.
 2011
 29 Supplement 2 p. 5078-5086
9 p.
 article
94 Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats Bréard, E.
 2011
 29 Supplement 2 p. 2495-2502
8 p.
 article
95 Evaluation of the immune response induced by DNA vaccine cocktail expressing complete SAG1 and ROP2 genes against toxoplasmosis Hoseinian Khosroshahi, K.
 2011
 29 Supplement 2 p. 778-783
6 p.
 article
96 Evaluation of the immunogenicity and the protective efficacy of a novel identified immunogenic protein, SsPepO, of Streptococcus suis serotype 2 Li, Jinquan
 2011
 29 Supplement 2 p. 6514-6519
6 p.
 article
97 Evaluation of the reliability, validity and practicality of 3 measures of acute pain in infants undergoing immunization injections Taddio, Anna
 2011
 29 Supplement 2 p. 1390-1394
5 p.
 article
98 Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis Dziadek, Bozena
 2011
 29 Supplement 2 p. 821-830
10 p.
 article
99 Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial Barreto, Mauricio L.
 2011
 29 Supplement 2 p. 4875-4877
3 p.
 article
100 Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia Gray, Richard T.
 2011
 29 Supplement 2 p. 6125-6129
5 p.
 article
101 Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines Gil, Cristina
 2011
 29 Supplement 2 p. 5711-5724
14 p.
 article
102 Gene expression profiling in naïve and vaccinated rainbow trout after Yersinia ruckeri infection: Insights into the mechanisms of protection seen in vaccinated fish Harun, Nor Omaima
 2011
 29 Supplement 2 p. 4388-4399
12 p.
 article
103 Genetic polymorphisms in host antiviral genes: Associations with humoral and cellular immunity to measles vaccine Haralambieva, Iana H.
 2011
 29 Supplement 2 p. 8988-8997
10 p.
 article
104 Guillain–Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition Choe, Young June
 2011
 29 Supplement 2 p. 2066-2070
5 p.
 article
105 Guillain–Barré Syndrome in India: Population-based validation of the Brighton criteria Mateen, Farrah J.
 2011
 29 Supplement 2 p. 9697-9701
5 p.
 article
106 Haemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre- and post-vaccine eras Jacups, Susan P.
 2011
 29 Supplement 2 p. 3083-3088
6 p.
 article
107 Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009 Lu, Peng-jun
 2011
 29 Supplement 2 p. 7049-7057
9 p.
 article
108 Hepatitis B vaccination coverage in healthcare workers in Gauteng Province, South Africa Burnett, Rosemary J.
 2011
 29 Supplement 2 p. 4293-4297
5 p.
 article
109 Hepatitis B virus markers among teenagers in the Araguaia region, Central Brazil: Assessment of prevalence and vaccination coverage Melo, Laura Valdiane Luz
 2011
 29 Supplement 2 p. 5290-5293
4 p.
 article
110 High burden of tick-borne encephalitis in Slovenia—Challenge for vaccination policy Grgič-Vitek, Marta
 2011
 29 Supplement 2 p. 5178-5183
6 p.
 article
111 Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmission of virulent virus Devlin, Joanne M.
 2011
 29 Supplement 2 p. 5699-5704
6 p.
 article
112 Horizontal transmission of a human rotavirus vaccine strain—A randomized, placebo-controlled study in twins Rivera, Luis
 2011
 29 Supplement 2 p. 9508-9513
6 p.
 article
113 HPV vaccine and adolescent males Reiter, Paul L.
 2011
 29 Supplement 2 p. 5595-5602
8 p.
 article
114 Human antibody and memory B and T-cell responses after primary and booster immunisation against Neisseria meningitidis B Cruz, Simone C.
 2011
 29 Supplement 2 p. 7387-7394
8 p.
 article
115 Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA Santamaria, Raquel
 2011
 29 Supplement 2 p. 8689-8695
7 p.
 article
116 Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins Hendrikx, Lotte H.
 2011
 29 Supplement 2 p. 1431-1437
7 p.
 article
117 IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice van Es, Thomas
 2011
 29 Supplement 2 p. 976-983
8 p.
 article
118 ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors Kovjazin, Riva
 2011
 29 Supplement 2 p. 4676-4686
11 p.
 article
119 Immune evaluation and vaccine responses in Down syndrome: Evidence of immunodeficiency? Joshi, Avni Y.
 2011
 29 Supplement 2 p. 5040-5046
7 p.
 article
120 Immune response of Atlantic salmon to recombinant flagellin Hynes, Natasha A.
 2011
 29 Supplement 2 p. 7678-7687
10 p.
 article
121 Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection Liu, Min
 2011
 29 Supplement 2 p. 1745-1753
9 p.
 article
122 Immunity against diphtheria among children and adults in Izmir, Turkey Kurugöl, Zafer
 2011
 29 Supplement 2 p. 4341-4344
4 p.
 article
123 Immunization of female BALB/c mice with Neospora cyclophilin and/or NcSRS2 elicits specific antibody response and prevents against challenge infection by Neospora caninum Tuo, Wenbin
 2011
 29 Supplement 2 p. 2392-2399
8 p.
 article
124 Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea Lee, Soo Young
 2011
 29 Supplement 2 p. 1551-1557
7 p.
 article
125 Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study Bernstein, Henry H.
 2011
 29 Supplement 2 p. 2212-2221
10 p.
 article
126 Immunogenicity and safety of a Haemophilus influenzae B (Hib)–hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants Lee, Andrew W.
 2011
 29 Supplement 2 p. 7942-7948
7 p.
 article
127 Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses Rümke, H.C.
 2011
 29 Supplement 2 p. 3842-3849
8 p.
 article
128 Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study Rusnak, Janice M.
 2011
 29 Supplement 2 p. 3222-3229
8 p.
 article
129 Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children Saksawad, Rachanee
 2011
 29 Supplement 2 p. 4735-4738
4 p.
 article
130 Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China Li, Rong Cheng
 2011
 29 Supplement 2 p. 1913-1920
8 p.
 article
131 Immunogenicity and safety of a single intramuscular dose of a diphtheria–tetanus toxoid (Td) vaccine (GC1107) in Korean adults Lee, SeungHwan
 2011
 29 Supplement 2 p. 7638-7643
6 p.
 article
132 Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study Grimprel, Emmanuel
 2011
 29 Supplement 2 p. 7370-7378
9 p.
 article
133 Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term Polish infants Szynczewska, Ewa
 2011
 29 Supplement 2 p. 7107-7113
7 p.
 article
134 Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea Cheong, Hee Jin
 2011
 29 Supplement 2 p. 523-527
5 p.
 article
135 Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children Phongsamart, Wanatpreeya
 2011
 29 Supplement 2 p. 8705-8711
7 p.
 article
136 Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years Abarca, Katia
 2011
 29 Supplement 2 p. 8855-8862
8 p.
 article
137 Immunogenicity assay validation for an HIV vaccine trial: High IFNγ+/IL-2+ CD8+ T cells background in healthy Thais Sirivichayakul, Sunee
 2011
 29 Supplement 2 p. 6002-6007
6 p.
 article
138 Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys Koeberling, Oliver
 2011
 29 Supplement 2 p. 4728-4734
7 p.
 article
139 Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein Iankov, Ianko D.
 2011
 29 Supplement 2 p. 1710-1720
11 p.
 article
140 Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration Cherif, Mahamoud Sama
 2011
 29 Supplement 2 p. 9038-9050
13 p.
 article
141 Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix ®) in adults 55 years of age and over: A sub-analysis of four trials Van Damme, Pierre
 2011
 29 Supplement 2 p. 5932-5939
8 p.
 article
142 Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants Vesikari, T.
 2011
 29 Supplement 2 p. 2079-2084
6 p.
 article
143 Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006–2007 Anh, D.D.
 2011
 29 Supplement 2 p. 2029-2036
8 p.
 article
144 Immunoglobulin deficiency in children with Hib vaccine failure Ladhani, Shamez
 2011
 29 Supplement 2 p. 9137-9140
4 p.
 article
145 Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized Miura, Kazutoyo
 2011
 29 Supplement 2 p. 2255-2261
7 p.
 article
146 Immunological responses induced by a DNA vaccine expressing RON4 and by immunogenic recombinant protein RON4 failed to protect mice against chronic toxoplasmosis Rashid, Imran
 2011
 29 Supplement 2 p. 8838-8846
9 p.
 article
147 Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age Wilson, Kumanan
 2011
 29 Supplement 2 p. 8267-8274
8 p.
 article
148 Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges Hanquet, Germaine
 2011
 29 Supplement 2 p. 2856-2864
9 p.
 article
149 Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age Hendrikx, Lotte H.
 2011
 29 Supplement 2 p. 5725-5730
6 p.
 article
150 Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study Gagneur, Arnaud
 2011
 29 Supplement 2 p. 3753-3759
7 p.
 article
151 Implementation and evaluation of the Reaching Every District (RED) strategy in Assam, India, 2005–2008 Ryman, Tove K.
 2011
 29 Supplement 2 p. 2555-2560
6 p.
 article
152 Implementation of mandatory immunisation of healthcare workers: Observations from New South Wales, Australia Helms, Charles
 2011
 29 Supplement 2 p. 2895-2901
7 p.
 article
153 Improvement of the immunity of pig to Hog cholera vaccine by recombinant plasmid with porcine interleukin-6 gene and CpG motifs Li, Dong
 2011
 29 Supplement 2 p. 3888-3894
7 p.
 article
154 Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response Moraes, Mauro Pires
 2011
 29 Supplement 2 p. 9431-9440
10 p.
 article
155 Increasing vaccine potency through exosome antigen targeting Hartman, Zachary C.
 2011
 29 Supplement 2 p. 9361-9367
7 p.
 article
156 Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: Comparative analysis from Brazil, India, and South Africa Griffiths, Ulla K.
 2011
 29 Supplement 2 p. 969-975
7 p.
 article
157 In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization Zhao, Qinjian
 2011
 29 Supplement 2 p. 7936-7941
6 p.
 article
158 Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) Taylor, David N.
 2011
 29 Supplement 2 p. 4897-4902
6 p.
 article
159 Induction of protective immunity against Eimeria tenella infection using antigen-loaded dendritic cells (DC) and DC-derived exosomes del Cacho, Emilio
 2011
 29 Supplement 2 p. 3818-3825
8 p.
 article
160 Induction of protective Th1 immune responses in mice by vaccination with recombinant Toxoplasma gondii nucleoside triphosphate hydrolase-II Tan, Feng
 2011
 29 Supplement 2 p. 2742-2748
7 p.
 article
161 Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines Park, H.J.
 2011
 29 Supplement 2 p. 3476-3482
7 p.
 article
162 Infection of mouse bone marrow-derived dendritic cells by live attenuated Japanese encephalitis virus induces cells maturation and triggers T cells activation Li, Yaoming
 2011
 29 Supplement 2 p. 855-862
8 p.
 article
163 Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial Plennevaux, Eric
 2011
 29 Supplement 2 p. 1569-1575
7 p.
 article
164 Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results Belongia, Edward A.
 2011
 29 Supplement 2 p. 6558-6563
6 p.
 article
165 Innate immunity in DNA vaccine with Toxoplasma gondii-heat shock protein 70 gene that induces DC activation and Th1 polarization Makino, Masayuki
 2011
 29 Supplement 2 p. 1899-1905
7 p.
 article
166 Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication Pallikkuth, Suresh
 2011
 29 Supplement 2 p. 9229-9238
10 p.
 article
167 Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine Velasquez, Lissette S.
 2011
 29 Supplement 2 p. 5221-5231
11 p.
 article
168 In vitro analysis of the factors contributing to the antiviral state induced by a plasmid encoding the viral haemorrhagic septicaemia virus glycoprotein G in transfected trout cells Ortega-Villaizan, M.
 2011
 29 Supplement 2 p. 737-743
7 p.
 article
169 Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda Fadnes, Lars T.
 2011
 29 Supplement 2 p. 3564-3570
7 p.
 article
170 Lack of correlation between BCG-induced tuberculin skin test sensitisation and protective immunity in cattle Whelan, A.O.
 2011
 29 Supplement 2 p. 5453-5458
6 p.
 article
171 Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines Capeding, Rosario Z.
 2011
 29 Supplement 2 p. 3863-3872
10 p.
 article
172 Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents Zingone, F.
 2011
 29 Supplement 2 p. 1005-1008
4 p.
 article
173 Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults Stermole, Benjamin M.
 2011
 29 Supplement 2 p. 2874-2880
7 p.
 article
174 Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide® ISA 720 and stabilized with glycine Zhu, Daming
 2011
 29 Supplement 2 p. 3640-3645
6 p.
 article
175 LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb Nawar, Hesham F.
 2011
 29 Supplement 2 p. 721-727
7 p.
 article
176 Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers Rynkiewicz, Dianna
 2011
 29 Supplement 2 p. 6313-6320
8 p.
 article
177 Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells Cereda, Vittore
 2011
 29 Supplement 2 p. 4992-4999
8 p.
 article
178 Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules Fraternale, Alessandra
 2011
 29 Supplement 2 p. 6823-6829
7 p.
 article
179 Molecular and infectivity studies of porcine circovirus in vaccines McClenahan, Shasta D.
 2011
 29 Supplement 2 p. 4745-4753
9 p.
 article
180 Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: Revisiting the role of host innate susceptibility and routes of challenge Simon, Raphael
 2011
 29 Supplement 2 p. 5094-5106
13 p.
 article
181 Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination Baatarjav, Tselmeg
 2011
 29 Supplement 2 p. 5747-5757
11 p.
 article
182 Mycobacterium bovis (Bacille Calmette-Guérin) bacteremia in immunocompetent neonates following vaccination Thamthitiwat, Somsak
 2011
 29 Supplement 2 p. 1727-1730
4 p.
 article
183 MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes Mendes, Érica A.
 2011
 29 Supplement 2 p. 4476-4484
9 p.
 article
184 Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine Kuo, Chen-Yen
 2011
 29 Supplement 2 p. 5171-5177
7 p.
 article
185 Neuropathology of vaccination in infants and children Rorke-Adams, Lucy B.
 2011
 29 Supplement 2 p. 8754-8759
6 p.
 article
186 Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin® Doukas, John
 2011
 29 Supplement 2 p. 5443-5452
10 p.
 article
187 Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs Beach, Nathan M.
 2010
 29 Supplement 2 p. 221-232
12 p.
 article
188 Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines Wiggan, O’Neil
 2011
 29 Supplement 2 p. 7456-7462
7 p.
 article
189 Novel gene isolated from Caligus rogercresseyi: A promising target for vaccine development against sea lice Carpio, Yamila
 2011
 29 Supplement 2 p. 2810-2820
11 p.
 article
190 Of mice and not humans: How reliable are animal models for evaluation of herpes CD8+-T cell-epitopes-based immunotherapeutic vaccine candidates? Dasgupta, Gargi
 2011
 29 Supplement 2 p. 5824-5836
13 p.
 article
191 “Once Bitten, Twice Shy”: Participant perspectives in the aftermath of an early HIV vaccine trial termination Newman, P.A.
 2011
 29 Supplement 2 p. 451-458
8 p.
 article
192 “Once I begin to participate, people will run away from me”: Understanding stigma as a barrier to HIV vaccine research participation in Kenya Nyblade, Laura
 2011
 29 Supplement 2 p. 8924-8928
5 p.
 article
193 Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age Russell, F.M.
 2011
 29 Supplement 2 p. 535-544
10 p.
 article
194 Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans Wu, Jiang
 2011
 29 Supplement 2 p. 1009-1016
8 p.
 article
195 Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice Cao, Jie
 2011
 29 Supplement 2 p. 3714-3723
10 p.
 article
196 Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice Singh, Vipul K.
 2011
 29 Supplement 2 p. 4754-4760
7 p.
 article
197 Pandemic influenza A (H1N1) vaccination in The Netherlands: Parental reasoning underlying child vaccination choices Bults, Marloes
 2011
 29 Supplement 2 p. 6226-6235
10 p.
 article
198 Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination Lagler, Heimo
 2011
 29 Supplement 2 p. 6888-6893
6 p.
 article
199 Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques Marthas, Marta L.
 2011
 29 Supplement 2 p. 3124-3137
14 p.
 article
200 Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs Tarradas, Joan
 2011
 29 Supplement 2 p. 4422-4429
8 p.
 article
201 Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris Liu, Pei-Feng
 2011
 29 Supplement 2 p. 3230-3238
9 p.
 article
202 Pathogenicity of SG 9R, a rough vaccine strain against fowl typhoid Kwon, Hyuk-Joon
 2011
 29 Supplement 2 p. 1311-1318
8 p.
 article
203 Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations—A population based study of 969,519 vaccination events Wilson, Kumanan
 2011
 29 Supplement 2 p. 3746-3752
7 p.
 article
204 Pekin and Muscovy ducks respond differently to vaccination with a H5N1 highly pathogenic avian influenza (HPAI) commercial inactivated vaccine Cagle, Caran
 2011
 29 Supplement 2 p. 6549-6557
9 p.
 article
205 Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine Weston, Wayde
 2011
 29 Supplement 2 p. 8483-8486
4 p.
 article
206 Pertussis – An under-diagnosed disease with high morbidity in Singapore children Goh, Anne
 2011
 29 Supplement 2 p. 2503-2507
5 p.
 article
207 Pharmacists as providers: Targeting pneumococcal vaccinations to high risk populations Taitel, Michael
 2011
 29 Supplement 2 p. 8073-8076
4 p.
 article
208 Phenotypic localization of distinct DC subsets in mouse Peyer Patch Rochereau, Nicolas
 2011
 29 Supplement 2 p. 3655-3661
7 p.
 article
209 Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds Murata, Haruhiko
 2011
 29 Supplement 2 p. 3155-3161
7 p.
 article
210 Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance van den Biggelaar, Anita H.J.
 2011
 29 Supplement 2 p. 5414-5420
7 p.
 article
211 Poliomyelitis outbreaks in Angola genetically linked to India: Risk factors and implications for prevention of outbreaks due to wild poliovirus importations Kidd, Sarah
 2011
 29 Supplement 2 p. 3760-3766
7 p.
 article
212 Potential protective immunogenicity of recombinant Clostridium perfringens α–β2–β1 fusion toxin in mice, sows and cows Zeng, Jin
 2011
 29 Supplement 2 p. 5459-5466
8 p.
 article
213 Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model Skinner, Julie M.
 2011
 29 Supplement 2 p. 8870-8876
7 p.
 article
214 Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes Niu, Liguo
 2011
 29 Supplement 2 p. 2110-2119
10 p.
 article
215 Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule Wiertsema, Selma P.
 2011
 29 Supplement 2 p. 5163-5170
8 p.
 article
216 Preliminary assessment of binary ethylenimine inactivated and saponized cutaneous warts (BPV-2) therapeutic vaccine for enzootic bovine haematuria in hill cows Pathania, S.
 2011
 29 Supplement 2 p. 7296-7302
7 p.
 article
217 Preservative of choice for Prev(e)nar 13™ in a multi-dose formulation Khandke, Lakshmi
 2011
 29 Supplement 2 p. 7144-7153
10 p.
 article
218 Prevenar experience Arguedas, Adriano
 2011
 29 Supplement 2 p. C26-C34
nvt p.
 article
219 Prevention of pneumococcal disease through vaccination Gentile, Angela
 2011
 29 Supplement 2 p. C15-C25
nvt p.
 article
220 Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines Quenee, Lauriane E.
 2011
 29 Supplement 2 p. 6572-6583
12 p.
 article
221 Primary care physician perspectives on providing adult vaccines Freed, Gary L.
 2011
 29 Supplement 2 p. 1850-1854
5 p.
 article
222 Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus Xue, Wenzhi
 2011
 29 Supplement 2 p. 4657-4662
6 p.
 article
223 Protection of Eurasian badgers (Meles meles) from tuberculosis after intra-muscular vaccination with different doses of BCG Lesellier, Sandrine
 2011
 29 Supplement 2 p. 3782-3790
9 p.
 article
224 Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain Minke, J.M.
 2011
 29 Supplement 2 p. 4608-4612
5 p.
 article
225 Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine Ashraf, Shamaila
 2011
 29 Supplement 2 p. 3990-4002
13 p.
 article
226 Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB) Yermakova, Anastasiya
 2011
 29 Supplement 2 p. 7925-7935
11 p.
 article
227 Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation Silveira, F.
 2011
 29 Supplement 2 p. 9177-9182
6 p.
 article
228 Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression Bunupuradah, Torsak
 2011
 29 Supplement 2 p. 2962-2967
6 p.
 article
229 Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults Leeb, Alan
 2011
 29 Supplement 2 p. 7920-7924
5 p.
 article
230 Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: Towards an in vitro assay for vaccine immunogenicity Hoefnagel, Marcel H.N.
 2011
 29 Supplement 2 p. 5114-5121
8 p.
 article
231 Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients Meerveld-Eggink, A.
 2011
 29 Supplement 2 p. 675-680
6 p.
 article
232 Risk of disability for US army personnel vaccinated against anthrax, 1998–2005 Sulsky, Sandra I.
 2011
 29 Supplement 2 p. 6035-6041
7 p.
 article
233 Rotavirus shedding in premature infants following first immunization Smith, Candice K.
 2011
 29 Supplement 2 p. 8141-8146
6 p.
 article
234 RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses van Bleek, Grada M.
 2011
 29 Supplement 2 p. 7285-7291
7 p.
 article
235 Safety and immunogenicity of a candidate parvovirus B19 vaccine Bernstein, David I.
 2011
 29 Supplement 2 p. 7357-7363
7 p.
 article
236 Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) García, Felipe
 2011
 29 Supplement 2 p. 8309-8316
8 p.
 article
237 Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults Turley, Christine B.
 2011
 29 Supplement 2 p. 5145-5152
8 p.
 article
238 Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico López-Macías, Constantino
 2011
 29 Supplement 2 p. 7826-7834
9 p.
 article
239 Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons Wald, Anna
 2011
 29 Supplement 2 p. 8520-8529
10 p.
 article
240 Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age Diaz-Mitoma, Francisco
 2011
 29 Supplement 2 p. 1324-1331
8 p.
 article
241 Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis Wang, Ling-yun
 2011
 29 Supplement 2 p. 2679-2681
3 p.
 article
242 Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age Saha, Amit
 2011
 29 Supplement 2 p. 8285-8292
8 p.
 article
243 Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh Rahman, Kazi Mizanur
 2011
 29 Supplement 2 p. 1347-1354
8 p.
 article
244 Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance Kurz, Xavier
 2011
 29 Supplement 2 p. 4378-4387
10 p.
 article
245 Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus Satoh, Ryoichi
 2011
 29 Supplement 2 p. 1791-1800
10 p.
 article
246 Seasonal influenza vaccination in adults: Practice and attitudes about collaborative delivery with community vaccinators Hurley, Laura P.
 2011
 29 Supplement 2 p. 8649-8655
7 p.
 article
247 Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths Alexander, Neal
 2011
 29 Supplement 2 p. 3686-3694
9 p.
 article
248 Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells Goulart, Cibelly
 2011
 29 Supplement 2 p. 1634-1642
9 p.
 article
249 Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS) Poethko-Müller, Christina
 2011
 29 Supplement 2 p. 7949-7959
11 p.
 article
250 Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months Russell, F.M.
 2011
 29 Supplement 2 p. 4499-4506
8 p.
 article
251 Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6–59 months of age Mallory, Raburn M.
 2011
 29 Supplement 2 p. 4322-4327
6 p.
 article
252 Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library Neri, Paola
 2011
 29 Supplement 2 p. 5340-5346
7 p.
 article
253 Smallpox eradication in Bangladesh, 1972–1976 Foster, Stanley O.
 2011
 29 Supplement 2 p. D22-D29
nvt p.
 article
254 Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods Patois, E.
 2011
 29 Supplement 2 p. 7404-7413
10 p.
 article
255 Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative Jauregui, Barbara
 2011
 29 Supplement 2 p. 1099-1106
8 p.
 article
256 Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China Liu, Xinyu
 2011
 29 Supplement 2 p. 2127-2130
4 p.
 article
257 Subcutaneous and intranasal immunization with Stx2B–Tir–Stx1B–Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice Zhang, Xue-han
 2011
 29 Supplement 2 p. 3923-3929
7 p.
 article
258 Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice Amuguni, J. Hellen
 2011
 29 Supplement 2 p. 4778-4784
7 p.
 article
259 Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy Levine, Hagai
 2011
 29 Supplement 2 p. 2785-2790
6 p.
 article
260 Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses Li, Shanfeng
 2011
 29 Supplement 2 p. 3695-3702
8 p.
 article
261 T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep Rojas, José-Manuel
 2011
 29 Supplement 2 p. 6848-6857
10 p.
 article
262 T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague Levy, Yinon
 2011
 29 Supplement 2 p. 6866-6873
8 p.
 article
263 Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants Verhaegh, Suzanne J.C.
 2011
 29 Supplement 2 p. 5603-5610
8 p.
 article
264 The burden of hospitalizations for meningococcal infection in Spain (1997–2008) Gil-Prieto, Ruth
 2011
 29 Supplement 2 p. 5765-5770
6 p.
 article
265 The current status of invasive pneumococcal disease in Poland Skoczyńska, Anna
 2011
 29 Supplement 2 p. 2199-2205
7 p.
 article
266 The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations Said, Maria A.
 2011
 29 Supplement 2 p. 5355-5362
8 p.
 article
267 The future of pneumococcal disease prevention Rodgers, Gail L.
 2011
 29 Supplement 2 p. C43-C48
nvt p.
 article
268 The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic Engelhard, Dan
 2011
 29 Supplement 2 p. 1777-1782
6 p.
 article
269 The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule Ota, Martin O.
 2011
 29 Supplement 2 p. 2999-3007
9 p.
 article
270 The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children Thanee, Chareeya
 2011
 29 Supplement 2 p. 5886-5891
6 p.
 article
271 The immunogenicity of pneumococcal polysaccharides in infants and children: A meta-regression Laferriere, Craig
 2011
 29 Supplement 2 p. 6838-6847
10 p.
 article
272 The incidence and direct medical cost of hospitalization due to rotavirus gastroenteritis in Kyoto, Japan, as estimated from a retrospective hospital study Ito, Hisato
 2011
 29 Supplement 2 p. 7807-7810
4 p.
 article
273 The 1918 influenza pandemic in Florianopolis: A subtropical city in Brazil Alonso, Wladimir J.
 2011
 29 Supplement 2 p. B16-B20
nvt p.
 article
274 The introduction of multi-copy CpG motifs into an antiviral DNA vaccine strongly up-regulates its immunogenicity in fish Martinez-Alonso, S.
 2011
 29 Supplement 2 p. 1289-1296
8 p.
 article
275 The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results Andersson, Kyeen M.
 2011
 29 Supplement 2 p. 6107-6112
6 p.
 article
276 The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model Hontelez, Jan A.C.
 2011
 29 Supplement 2 p. 6100-6106
7 p.
 article
277 Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies Dalgleish, Angus G.
 2011
 29 Supplement 2 p. 8501-8505
5 p.
 article
278 The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep Maggioli, Gabriela
 2011
 29 Supplement 2 p. 9057-9063
7 p.
 article
279 The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice Bernardo, Lidice
 2011
 29 Supplement 2 p. 4256-4263
8 p.
 article
280 Trends in US pediatric influenza vaccination from 2006 to 2010 among children with private insurance Toback, Seth L.
 2011
 29 Supplement 2 p. 4225-4229
5 p.
 article
281 Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model Kollessery, Gayathri
 2011
 29 Supplement 2 p. 5904-5910
7 p.
 article
282 Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in Denmark Harder, Katja Majlund
 2011
 29 Supplement 2 p. 9303-9307
5 p.
 article
283 Updated aluminum pharmacokinetics following infant exposures through diet and vaccination Mitkus, Robert J.
 2011
 29 Supplement 2 p. 9538-9543
6 p.
 article
284 Vaccine counseling: A content analysis of patient–physician discussions regarding human papilloma virus vaccine Goff, Sarah L.
 2011
 29 Supplement 2 p. 7343-7349
7 p.
 article
285 Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells Derrick, Steven C.
 2011
 29 Supplement 2 p. 2902-2909
8 p.
 article
286 Vaccinia virus as a vaccine delivery system for marsupial wildlife Cross, Martin L.
 2011
 29 Supplement 2 p. 4537-4543
7 p.
 article
287 Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response Charles-Niño, Claudia
 2011
 29 Supplement 2 p. 5313-5321
9 p.
 article
288 Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media Seppälä, Elina
 2011
 29 Supplement 2 p. 8615-8618
4 p.
 article
289 Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine Heyman, Katherine P.
 2011
 29 Supplement 2 p. 4618-4622
5 p.
 article
                             289 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands